| Display this index in Date order |
| Title & Synopsis | Date |
Price |
Order Form
|
| Actavis - Generic Company Intelligence Report Actavis has been one of the most acquisitive in the generic field in recent years, buying a large number of manufacturers and distributors. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Apotex - Generic Company Intelligence Report Apotex is Canada’s largest domestic pharmaceutical manufacturer. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Aspen Pharmacare - Generic Company Intelligence Report Aspen Pharmacare is Africa's largest manufacturer of generic drugs, and the leading supplier of generic products to both the private and public sectors in South Africa. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Aurobindo - Generic Company Intelligence Report India-based Aurobindo was founded in 1986, and became a public company in 1995. The firm has a multi product portfolio, and has manufacturing facilities in India, China, the US and Brazil.. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Barr Pharmaceuticals - Generic Company Intelligence Report Barr Pharmaceuticals is one of the USA’s leading generic manufacturers. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Oct-2009 |
£195/
$340/
€245 |
|
| Cipla - Generic Company Intelligence Report Cipla was founded in Bombay in 1935 and manufactures APIs and formulation drugs. Its products are sold in over 150 countries. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Dr Reddy's Laboratories - Generic Company Intelligence Report Dr Reddy’s is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Egis - Generic Company Intelligence Report Egis was established in 1913 in Budapest, Hungary. The company has 21 subsidiaries under its direct control. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Gedeon Richter - Generic Company Intelligence Report Gedeon Richter is Hungary's oldest and largest pharmaceutical manufacturer. It is one of the last major CEE pharmaceutical manufacturers not to be acquired by a multinational manufacturer. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Hospira - Generic Company Intelligence Report Hospira is a leading supplier of generic injectables in the USA, with a product range of 190 generic injectable products in more than 900 dosages and formulations. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Impax - Generic Company Intelligence Report Impax focuses on the development and commercialisation of generic and branded pharmaceuticals. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Krka - Generic Company Intelligence Report Krka was established in Slovenia in 1954, and has grown to become one of the largest generic drug manufacturers in Central and Eastern Europe. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Lannett - Generic Company Intelligence Report Lannett looks to developing generic drugs with more secure markets and less competition, while pursuing long-term alliances with API suppliers. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Lupin - Generic Company Intelligence Report Lupin's products are available in nearly 70 countries, with its overseas business accounting for around 65% of total revenues. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Mylan - Generic Company Intelligence Report Founded in 1961, Mylan, until 2007 known as Mylan Laboratories, is one of the largest US generic drug manufacturers. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Par Pharmaceutical - Generic Company Intelligence Report On 14th October 2008 Par announced resizing its generic unit but continues to develop and manufacture innovative branded pharmaceuticals for specialty markets. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Partnering in the Global Generics Industry 2009: A guide to companies Facts, statistics and insights on 170 medium-sized generic manufacturers from 40 countries. More>> |
Oct-2009 |
£595/
$1040/
€745 |
|
| Perrigo - Generic Company Intelligence Report Founded in 1887, Perrigo is the largest manufacturer of store brand OTCs and nutritional products in the United States. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Pliva - Generic Company Intelligence Report Pliva is based in Croatia, and is one of that country’s leading manufacturing companies. It is also one of the largest pharmaceutical manufacturers in central Europe. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Oct-2009 |
£195/
$340/
€245 |
|
| Ranbaxy - Generic Company Intelligence Report Acquired by Daiichi Sankyo in October 2008, Ranbaxy is India's leading pharmaceutical company and is at the forefront of attempts to bring cheaper generic HIV/AIDS medicines to developing countries. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| ratiopharm - Generic Company Intelligence Report ratiopharm, founded in 1974, claims to be the leading generic company in Germany, and the third largest pharmaceutical company overall, in terms of prescriptions. In January 2009, ratiopharm’s founder died. The VEM Group, which owns ratiopharm, confirmed in early 2009 that the company would be put up for sale. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Sandoz - Generic Company Intelligence Report Sandoz is currently the second largest generic manufacturer in the world, behind Teva Pharmaceutical Industries. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| sanofi-aventis - Generic Company Intelligence Report sanofi-aventis' forays into generics came initially through its Winthrop subsidiary, but have expanded in recent years, most notably with the acquisition of the Czech Republic-based Zentiva. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Sawai Pharmaceuticals - Generic Company Intelligence Report Sawai Pharmaceuticals is at the forefront of the Japanese generic market. It deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Simcere Pharmaceuticals - Generic Company Intelligence Report Simcere Pharmaceutical serves the Chinese pharmaceutical market. It deals in the export and import, manufacturing and sales of pharmaceutical products and healthcare foods. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Stada Arzneimittel - Generic Company Intelligence Report Stada Arzneimittel is one of the two major independent German generic manufacturers, along with ratiopharm. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Sun Pharmaceutical - Generic Company Intelligence Report India-based Sun Pharmaceutical Industries was established in 1983, initially selling psychiatry-related products in West Bengal and Bihar. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Teva Pharmaceutical Industries - Generic Company Intelligence Report Teva is the largest generic pharmaceutical manufacturer in the world. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| The World Generic Market Report 2010 This new 2 volume, 680-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face. More>> |
Jan-2010 |
£595/
$1040/
€745 |
|
| Watson Pharmaceuticals - Generic Company Intelligence Report Watson Pharmaceuticals was founded in 1984 in Corona, California. The company has facilities across the USA, and in the UK and China. It vies with Barr and Mylan as the USA’s largest generic manufacturer. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Wockhardt - Generic Company Intelligence Report The Indian company, Wockhardt Limited, was founded nearly four decades ago, and today claims its place amongst the country's top research and technology oriented pharmaceutical companies. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |
|
| Zentiva - Generic Company Intelligence Report Zentiva specialises in the development of generics, and holds leading market positions in both the Czech and Slovak Republics. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Oct-2009 |
£195/
$340/
€245 |
|
| Zydus Cadila - Generic Company Intelligence Report Cadila was founded in 1952, and was restructured in 1992 to become the Zydus Cadila Group. The Zydus Group is aiming to become one of the top three healthcare companies in India and a global player. This report provides an insight into the company, reviewing its current business structure and activities. More>> |
Apr-2010 |
£195/
$340/
€245 |